Comparative Outcomes of Teprotumumab and Tocilizumab in Thyroid Eye Disease: The First Retrospective Study from the United Arab Emirates and Gulf Region of the Middle East
Teprotumumab and tocilizumab improved TED outcomes, with teprotumumab showing trends toward better proptosis reduction and lower recurrence. Larger studies are needed to confirm these findings.
Authors
- Habibullah Eatamadi
Institutions
- Shaikh Khalifa Medical City (AE)
Publication Details
- Journal
- Seminars in Ophthalmology
- Published
- 2025-12-24
- DOI
- https://doi.org/10.1080/08820538.2025.2606981
- Primary Topic
- Ophthalmology and Eye Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00